Bio-Techne Corporation (TECH)

NMS – Real vaqt narxi. Valyuta: USD

72.78

+0.12 (0.17%)

Yopilishda: Nov 06, 2026, 4:00 PM EST

72.78

0.00 (0.00%)

Bozordan keyin: Nov 06, 2026, 4:00 PM EST

04.11.2026

BIO-TECHNE DECLARES DIVIDEND

MINNEAPOLIS, Nov. 3, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended September 30, 2026. The quarterly dividend will be payable November 23, 2026, to all common shareholders of record at the close of business on November 13, 2026, provided Bio-Techne's previously announced transaction with Merck KGaA, Darmstadt, Germany has not closed on or before the close of business on November 13, 2026.

02.11.2026

Bio-Techne's Q1 Earnings on Deck: What's in Store for the Stock?

TECH's Q1 earnings are on deck, with revenues and EPS growth expected as investors weigh segment performance and the pending $11.3 billion acquisition.

28.10.2026

Conestoga SMid Cap Composite Q3 2026 Portfolio Activity

We initiated a position in Allegro because vehicle electrification, driver-assistance systems and other electronic features are increasing chip content per vehicle. We initiated a position in Sterling Infrastructure because its scale and experience help it win complex, mission-critical projects. We sold Workiva stock to reduce the portfolio's exposure to software, which has been a battleground for investors as it's deemed a potential area of disruption for AI.

08.10.2026

Bio-Techne Expands Global GMP Manufacturing Network with New Bristol Facility to Advance Scalable Cell Therapy Development

Investment strengthens Bio-Techne's global GMP manufacturing infrastructure for cell therapy applications New Bristol facility expands GMP small molecule production capacity and complements recent investments in North America Combined capabilities across Bristol, St. Paul and Minneapolis support customers from discovery through commercial manufacturing MINNEAPOLIS, Oct. 8, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents and diagnostic products, today announced the opening of a new manufacturing facility for Good Manufacturing Practice (GMP) grade small molecules in Bristol, United Kingdom, further expanding the company's global capabilities to support the rapidly growing cell therapy market. The investment reflects Bio-Techne's commitment to helping therapy developers address one of the industry's most pressing challenges: establishing scalable, reproducible manufacturing processes that can support programs from early development through commercialization.

30.09.2026

INCY or TECH: Which Is the Better Value Stock Right Now?

Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Incyte (INCY) and Techne (TECH). But which of these two stocks is more attractive to value investors?

23.09.2026

Bio-Techne Shareholders Approve Acquisition by Merck KGaA, Darmstadt, Germany

MINNEAPOLIS, Sept. 23, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) ("Bio-Techne"), a global provider of life science tools, reagents and diagnostic products, announced that Bio-Techne shareholders voted to approve and adopt the definitive agreement under which Merck KGaA, Darmstadt, Germany proposes to acquire Bio-Techne (the "Merger Agreement") at a Special Meeting of Shareholders held today.

22.09.2026

Bio-Techne Opens New Customer Experience Center in Düsseldorf to Accelerate Scientific Discovery and Customer Collaboration

New flagship facility provides hands-on access to Bio-Techne technologies, workflows and scientific expertise Regional hub will support researchers and organizations across the DACH and broader EMEA regions Center strengthens collaboration, training and innovation within Europe's life sciences community MINNEAPOLIS and DÜSSELDORF, Germany, Sept. 22, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents and diagnostic products, today announced the opening of its new Customer Experience Center in Düsseldorf, Germany, a flagship facility designed to bring European customers closer to Bio-Techne's latest innovations and scientific expertise.

Videolar